Treat-to-target With Secukinumab in Axial Spondyloarthritis

Sponsor
Professor Mikkel Østergaard
Study ID
NCT03639740
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

A study of axSpA and AS receiving Secukinumab in a treat-to-target strategy.

Key Dates

Start date
Jan 15, 2019
Status verified
Jan 2019
Primary completion
Feb 28, 2021
Completion
Feb 28, 2021

Study Design

Enrollment
88 participants (estimated)
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Other: Secukinumab 150 mg 300 mg or tumor necrosis factor inhibitor
    Secukinumab 150 mg sc. injection once a week for four weeks (induction phase) and thereafter once a month. If patients do not achieve ASDAS remission they get increased dosage of Secukinumab 300 mg sc. injection once a month. If still no ASDAS remission patients change to a TNF-inhibitor

Primary Outcome Measure

Proportion of patients with a positive change in MRI-inflammation [ Time Frame: Comparison of week 16 and 24 ]

Central Contacts

Related Studies